PRCT Quote, Financials, Valuation and Earnings

Perspective Therapeutics has a net margin of -35.77% compared to PROCEPT BioRobotics's net margin of --. PROCEPT BioRobotics's return on equity of -29.12% beat Perspective Therapeutics's return on equity of --.

PROCEPT BioRobotics has a consensus price target of $76.88, signalling upside risk potential of 29.9%. On the other hand Perspective Therapeutics has an analysts' consensus of $13.8214 which suggests that it could grow by 388.39%. Given that Perspective Therapeutics has higher upside potential than PROCEPT BioRobotics, analysts believe Perspective Therapeutics is more attractive than PROCEPT BioRobotics.

PROCEPT BioRobotics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.112, suggesting its more volatile than the S&P 500 by 11.175%.

PROCEPT BioRobotics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PROCEPT BioRobotics pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.

PROCEPT BioRobotics quarterly revenues are $69.2M, which are larger than Perspective Therapeutics quarterly revenues of --. PROCEPT BioRobotics's net income of -$24.7M is lower than Perspective Therapeutics's net income of -$18.2M. Notably, PROCEPT BioRobotics's price-to-earnings ratio is -- while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PROCEPT BioRobotics is 12.61x versus 19.95x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

RxSight has a net margin of -35.77% compared to PROCEPT BioRobotics's net margin of -21.61%. PROCEPT BioRobotics's return on equity of -29.12% beat RxSight's return on equity of -10.39%.

PROCEPT BioRobotics has a consensus price target of $76.88, signalling upside risk potential of 29.9%. On the other hand RxSight has an analysts' consensus of $21.18 which suggests that it could grow by 27.45%. Given that PROCEPT BioRobotics has higher upside potential than RxSight, analysts believe PROCEPT BioRobotics is more attractive than RxSight.

PROCEPT BioRobotics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison RxSight has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

PROCEPT BioRobotics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. RxSight offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PROCEPT BioRobotics pays -- of its earnings as a dividend. RxSight pays out -- of its earnings as a dividend.

PROCEPT BioRobotics quarterly revenues are $69.2M, which are larger than RxSight quarterly revenues of $37.9M. PROCEPT BioRobotics's net income of -$24.7M is lower than RxSight's net income of -$8.2M. Notably, PROCEPT BioRobotics's price-to-earnings ratio is -- while RxSight's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PROCEPT BioRobotics is 12.61x versus 4.46x for RxSight. Usually stocks with elevated PS ratios are considered overvalued.

VolitionRX has a net margin of -35.77% compared to PROCEPT BioRobotics's net margin of -2201.34%. PROCEPT BioRobotics's return on equity of -29.12% beat VolitionRX's return on equity of --.

PROCEPT BioRobotics has a consensus price target of $76.88, signalling upside risk potential of 29.9%. On the other hand VolitionRX has an analysts' consensus of $2.92 which suggests that it could grow by 495.52%. Given that VolitionRX has higher upside potential than PROCEPT BioRobotics, analysts believe VolitionRX is more attractive than PROCEPT BioRobotics.

PROCEPT BioRobotics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison VolitionRX has a beta of 0.997, suggesting its less volatile than the S&P 500 by 0.339%.

PROCEPT BioRobotics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. VolitionRX offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PROCEPT BioRobotics pays -- of its earnings as a dividend. VolitionRX pays out -- of its earnings as a dividend.

PROCEPT BioRobotics quarterly revenues are $69.2M, which are larger than VolitionRX quarterly revenues of $246.4K. PROCEPT BioRobotics's net income of -$24.7M is lower than VolitionRX's net income of -$5.4M. Notably, PROCEPT BioRobotics's price-to-earnings ratio is -- while VolitionRX's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PROCEPT BioRobotics is 12.61x versus 33.84x for VolitionRX. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings has a net margin of -35.77% compared to PROCEPT BioRobotics's net margin of 0.18%. PROCEPT BioRobotics's return on equity of -29.12% beat Xtant Medical Holdings's return on equity of -26.62%.

PROCEPT BioRobotics has a consensus price target of $76.88, signalling upside risk potential of 29.9%. On the other hand Xtant Medical Holdings has an analysts' consensus of $1.75 which suggests that it could grow by 149.29%. Given that Xtant Medical Holdings has higher upside potential than PROCEPT BioRobotics, analysts believe Xtant Medical Holdings is more attractive than PROCEPT BioRobotics.

PROCEPT BioRobotics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of -0.124, suggesting its less volatile than the S&P 500 by 112.425%.

PROCEPT BioRobotics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PROCEPT BioRobotics pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

PROCEPT BioRobotics quarterly revenues are $69.2M, which are larger than Xtant Medical Holdings quarterly revenues of $32.9M. PROCEPT BioRobotics's net income of -$24.7M is lower than Xtant Medical Holdings's net income of $58K. Notably, PROCEPT BioRobotics's price-to-earnings ratio is -- while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PROCEPT BioRobotics is 12.61x versus 0.79x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.